Tag Archives: Gbola Amusa

Chardan Capital Reiterates a Buy Rating on Forte Biosciences (FBRX)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Forte Biosciences (FBRX – Research Report), with a price target of $110.00. The company’s shares closed last Wednesday at $46.52, close to its 52-week high

Analyst Explains Why They Downgraded Their Rating on Seres Therapeutics (MCRB)

Chardan Capital analyst Gbola Amusa downgraded Seres Therapeutics (MCRB – Research Report) to Hold today and set a price target of $27.50. The company’s shares closed last Thursday at $26.86. According to TipRanks.com, Amusa is a 5-star analyst with an

Analysts Offer Insights on Healthcare Companies: and Synlogic (NASDAQ: SYBX)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Synlogic (SYBX – Research Report) with bullish sentiments. Synlogic (SYBX) In a report issued on May 21, Gbola Amusa from Chardan

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX) and MEI Pharma (NASDAQ: MEIP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Forte Biosciences (FBRX – Research Report) and MEI Pharma (MEIP – Research Report) with bullish sentiments. Forte Biosciences (FBRX) In a report

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech (KRYS – Research Report) today and set a price target of $115.00. The company’s shares closed last Tuesday at $47.63. According to TipRanks.com, Amusa is a 5-star analyst

Krystal Biotech (KRYS) Received its Third Buy in a Row

After William Blair and H.C. Wainwright gave Krystal Biotech (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech today and set a